A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones

Endocrinology

Volumn 150, Issue 2, 2009, Pages 862-870

  Tagami, Tetsuya ^a   Yamamoto, Hiroyuki ^a   Moriyama, Kenji ^a   Sawai, Kuniko ^a   Usui, Takeshi ^a   Shimatsu, Akira ^a   Naruse, Mitsuhide ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; TELMISARTAN; TROGLITAZONE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CELLS, CULTURED; HORMONE ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; MUTANT PROTEINS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PROTEIN BINDING; RETINOID X RECEPTORS; SUBSTRATE SPECIFICITY; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 59649118827     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0502     Document Type: Article

References (63)

1. Weber MA 1997 Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 15(Suppl):S31-S36
2. Dahl of B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
3. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees 2003 Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759-766
4. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022-2031
5. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M 2001 Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890
6. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K 2003 Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76 -81
7. Sharpe M, Jarvis B, Goa KL 2001 Telmisartan: a review of its use in hypertension. Drugs 61:1501-1529
8. Schupp M, Janke J, Clasen R, Unger T, Kintscher U 2004 Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 109:2054-2057
9. Benson SC, Pershadsingh HA, HoCI,Chittiboyina A,Desai P, PravenecM, Qi N, Wang J, Avery MA, Kurtz TW 2004 Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:1-10
10. Umesono K, MurakamiKK, ThompsonCC, Evans RM1991 Directrepeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D receptors. Cell 65:1255-1266
11. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
12. Cavailles V, Dauvois S, Danielian PS, Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91: 10009-10013
13. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357
14. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK 1997 Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 272:25500-25506
15. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG 1998 The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci USA 95:7939-7944
16. Rachez C, Suldan Z, Ward J, Chang C-P, Burakov D, Erdjument-Bromage H, Tempst P, Freedman LP 1998 A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:1787-1800
17. Puigserver P, Wu Z, Park CW, Graves R, Wright M, SpiegelmanBM1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839
18. Chang CY, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, Mcdonnell DP 1999 Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Mol Cell Biol 19:8226-8239
19. Bannister A, Kouzarides 1996 The CBP co-activator is a histone acetyltransferase. Nature 384:641-643
20. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimetric activation complex with P/CAF and CBP/p300. Cell 90:569-580
21. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M-J, O'Malley BW 1997 Steroid receptor coac- tivator-1 is a histone acetyltransferase. Nature 389:194-198
22. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K 1998 The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 12:1638-1651
23. Brent GA, Dunn MK, Harney JW, Gulick T, Larsen PR, Moore DD 1989 Thyroid hormone aporeceptor represses T3-inducible promoters and blocks activity of the retinoic acid receptor. New Biol 1:329-336
24. Damm K, Thompson CC, Evans RM 1989 Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature 339:593-597
25. Shi Y, Hon M, Evans RM 2002 The peroxisome proliferators-activated receptor δ, an integrator of transcriptional repression and nuclear signaling. Proc Natl Acad Sci USA 99:2613-2618
26. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA,Kliewer SA,Gampe RT,McKee DD,Moore JT,Wilson TM1996 Structural determinants of ligand binding selectivity between the peroxisome proliferators-activated receptors. Proc Natl Acad Sci USA 98:13919-13924
27. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404
28. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451-454
29. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD 1995 Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94
30. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
31. SandeS, PrivalskyML1996 IdentificationofTRACs(T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol Endocrinol 10:813-825
32. Alland L,Muhle R, Hou Jr H, Potes J,Chin L, Schreiber-Agus N,DePinho RA 1997 Role for N-Cor and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49-55
33. Heinzel T, Lavinsky RM, Mullen T-M, Soderstrom M, Laherty CD, Torchia J, Yang W-M, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG 1997 A complex containing N-CoR, mSIN3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48
34. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSIN3 and histone deacetylase. Cell 89:373-380
35. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395: 137-143
36. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A 1998Crystal structure of the ligand binding domain of the human nuclear receptor PPARy. J Biol Chem 273:31108-3111222
37. Tagami T, Madison LD, Nagaya T, Jameson JL 1997 Nuclear receptor core- pressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 17:2642-2648
38. Tagami T, Park Y, Jameson JL 1999 Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. J Biol Chem 274:22345-22353
39. Tagami T, Kopp P, Johnson W, Arseven OK, Jameson JL 1998 The thyroid hormone receptor variant a2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressor. Endocrinology 139:2535-2544
40. Tagami T, Lutz WH, Kumar R, Jameson JL 1998 The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Bio- chem Biophys Res Commun 253:358-363
41. Tagami T, Gu W, Peairs PT, West BL, Jameson JL 1998 A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol 12:1888-1902
42. Tagami T, JamesonJL 1998 Nuclear corepressors enhance the dominantneg- ative activity of mutant receptors that cause resistance to thyroid hormone. Endocrinology 139:640-650
43. Tagami T, Nakamura H, Sasaki S, Miyoshi Y, Imura H 1993 Estimation of the protein content of thyroid hormone receptor α1 and β1 in rat tissues by Western blotting. Endocrinology 132:275-279
44. Scheen AJ 2004 Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64:2537-2565
45. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559
46. Yusuf S, Gerstein H, Hoogwerf B, Pogue J,BoschJ,Wolffenbuttel BH, Zinman B 2001 Ramipril and the development of diabetes. JAMA 286:1882-1885
47. Cheng-LaiA, Levine A 2000 Rosiglitazone: an agent from the thoazolidinedi- one class for the treatment of type 2 diabetes. Heart Dis 2:326-333
48. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690-697
49. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
50. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-γ ligand-binding domain bound to all- trans retinoic acid. Nature 378:681-689
51. Feng W, Ribeiro RcJ, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280:1747-1749
52. DarimontBD, WagnerRL,AprilettiJW, StallcupMR,KushnerPJ, BaxterJD, Fletterick RJ, Yamamoto KR 1998 Structure and specificity of nuclear recep- tor-coactivator interactions. Genes Dev 12:3343-3356
53. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
54. Torchia J, Rose DW, Inostrova J, Kamei Y, WestinS,GlassCK, RosenfeldMG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear- receptor function. Nature 387:677-684
55. LeDouarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P, Losson R 1995 The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 14: 2020-2033
56. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
57. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletterick RJ, Baxter JD, West BL 2002 TR surfaces and conformations required to bind nuclear receptor corepressor. Mol Endocrinol 16:271-286
58. Nagy L, Kao H-Y, Love JD, LiC, BanayoE,Gooch JT, Chatterjee VKK, Evans RM, Schwabe JWR 1999 Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 13:3209 -3216
59. Gampe Jr RT, Montana VG, Lambert MH, Millaer AB, BledsoeRK, Milburn MV, Kliewer TM, Xu HE 2000 Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555
60. Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, Thomsen B, Bendixen C, Mandrup S, Kristiansen K 2002 Nuclear receptor corepressor- dependent repression of peroxisome proliferators-activated receptor Δ-mediated transactivation. Biochem J 363:157-165
61. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 Aperoxisomeproliferator-activatedreceptorγligandinhibitsadipocyte differentiation. Proc Natl Acad Sci USA 96:6102-6106
62. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE 2003 Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 17: 662-676
63. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U 2005 Molecular characterization of new selective peroxisome proliferators-activated receptor-γ modulators with an- giotensin receptor blocking activity. Diabetes 54:3442-3452